Pharmacosmos

Pharmacosmos was founded in 1965 by Henry Marinus Christensen, M.D., Ph.D., in Denmark. The company began its journey with a focus on developing and manufacturing pharmaceutical drug products and active pharmaceutical ingredients (API). Henry's vision was to create a company that could address iron deficiency, a prevalent health issue, with innovative solutions.

In 1993, leadership transitioned to Henry's youngest son, Lars Christensen, M.D., who took over as CEO. Under Lars's guidance, Pharmacosmos expanded its reach beyond Denmark, establishing a presence in the United States, United Kingdom, Ireland, Germany, Sweden, Norway, and China. This expansion was pivotal in positioning Pharmacosmos as a leader in the iron deficiency market.

Throughout its history, Pharmacosmos has remained a family-owned business, which has allowed it to maintain a strong focus on its core values and mission. The company's commitment to innovation and quality has been recognized globally, leading to partnerships with other pharmaceutical companies to enhance its distribution network.

Pharmacosmos has not only focused on product development but also on research, investing significantly in understanding iron deficiency and its impact on health. This dedication to research has enabled the company to develop products that are both effective and safe for patients worldwide.

Today, Pharmacosmos continues to thrive as a testament to the Christensen family's vision and dedication. The company's journey from a small Danish firm to a global player in the pharmaceutical industry highlights the impact of strong leadership and a commitment to addressing critical health issues.